

Table SI. Summary of author, study year, number of patients, location and duration of lesions, therapies and their efficacy results

Author	Year	Patients <i>n</i>	Age at presenta- tion, years/ Sex	Presentation	Duration of lesion, months	Treatment	Success of treatment
Castellano-Howard et al. (8)	2000	1	57/M	Face, chest, back	480	Oral dapsone therapy 50 mg daily × 1 month, subsequently increased to 100 mg daily.	Little impr.
Elston (9)	2000	1	54/M	Face	120	Topical corticosteroid therapy Oral dapsone therapy for 2 years Candela™ pulsed dye laser (6.5 J/cm ²) single Candela™ pulsed dye laser (7.0 J/cm ²) pulse to each lesion × 2	No benefit No benefit No benefit
Gomez-de la Fuente et al. (10)	2000	1	72/M	Nose	120	Clofazimine 300 mg daily for 5 months	CR Remarkable
Burns et al. (11)	2001	1	38/M	Nose	24	Intralesional injection of steroids 1-month prednisolone orally Oral dapsone therapy for 3 years. YAGg laser (532.nm, i.e. green)	No benefit No benefit No benefit Little impr.
Inanir & Alvir (12)	2001	1	47/F	Face, neck, arm	24	Topical mometasone × 6 weeks	Complete remission
Cecchi et al. (13)	2002	1	72/M	Temple	6	Dapsone 100 mg daily and betamethasone dipropionate 0.5%	Not successful
Chatrath & Rohrer (14)	2002	1	55/M	Nasolabial fold	24	3 × long-pulsed tunable dye laser with a single pass using a 7-mm round spot-size with a 3-ms pulse duration, at 595 nm, and 9.5–12 J/cm ² .	CR
Hsiung (15)	2003	1	52/M	Cheek, nose	60	Intralesional triamcinolone (5 mg/ml) once and topical fluocinonide ointment	No benefit
Ludwig et al. (16)	2003	1	74/F	Cheek, forehead	12	Local, systemic treatments such as glucocorticosteroids or ultraviolet (UV) therapy Daily treatment with KTP 532-nm laser, fluence of 20 J/cm ² , a duration of application of 15 ms, a pulse rate of 6 s-1 and 3 passes with the 1-mm handpiece.	Without any long-term benefit CR
Ludwig et al. (16)	2003	1	67/M	Temple	6	KTP 532-nm laser with a fluence of 25 J/cm ² , duration of application of 18 ms, pulse rate 5 Hz	CR
Ludwig et al. (16)	2003	1	64/F	Forehead, cheeks, nose	72	Topical tacrolimus 0.1% ointment twice daily	Most lesions resolved
Radin & Mehregan (17)	2003	1	58/F	Eyebrow	Nk	High-potency topical steroid	Marked impr.
Radin & Mehregan (17)	2003	1	58/F	Nose	Nk	Intralesional steroid	Resolved
Radin & Mehregan (17)	2003	1	79/M	Neck	Nk	Topical steroid	Resolved
Radin & Mehregan (17)	2003	1	63/M	Cheek	Nk	Steroid tape	Resolved
Radin & Mehregan (17)	2003	1	69/F	Cheek	Nk	Intralesional steroid	Impr.
Radin & Mehregan (17)	2003	1	43/M	Forehead	Nk	Doxycycline 100 mg orally 4x/day with intralesional steroid	Marked impr.
Radin & Mehregan (17)	2003	1	68/F	Nose	Nk	Intralesional steroid	Marked impr.
Radin & Mehregan (17)	2003	1	42/M	Temple	Nk	Intralesional steroid, topical steroid, liquid nitrogen	Modest impr.
Radin & Mehregan (17)	2003	1	78/F	Cheek	Nk	Topical steroid	Mild impr.
Radin & Mehregan (17)	2003	1	70/M	Scalp	Nk	Topical and intralesional steroids	Mild impr.
Radin & Mehregan (9/38 included) (17)	2003	1	63/F	Cheek	Nk	Intralesional steroid	Fair impr.
Roussaki-Schulze et al. (18)	2003	1	65/M	Forehead, cheek, neck and back	120	Antiandrogen therapy of the prostate adenocarcinoma.	Regression
Chinelli et al. (19)	2004	1	31/F	Face, back	24	Oral dapsone therapy 100 mg daily. Monthly intralesional injections of 5 mg/ml triamcinolone × 8.	Significant impr.
Mitchell (20)	2004	1	59/M	Cheeks	48	Excision Intralesional corticosteroids Topical tacrolimus ointment (0.1% twice daily)	Recurrence Not successful Near total regression
Zargari (21)	2004	1	40/M	Cheeks, arm, breast	36	3 × liquid nitrogen for 20 s followed immediately by intralesional triamcinolone acetonide (5 mg/ml)	Partial resolution
Cheung & Lanigan (22)	2005	1	62/M	Temple	Nk	7-mm overlapping spot at 10–14 J/cm ² and pulse duration of 1–3 ms	Not successful
Cheung & Lanigan (22)	2005	1	52/M	Cheek	Nk	7-mm overlapping spot at 10–14 J/cm ² and pulse duration of 1–3 ms	Not successful
Cheung & Lanigan (22)	2005	1	60/M	Nose	Nk	7-mm overlapping spot at 10–14 J/cm ² and pulse duration of 1–3 ms	Significant cosmetic impr.
Cheung & Lanigan (22)	2005	1	52/M	Nose	Nk	7-mm overlapping spot at 10–14 J/cm ² and pulse duration of 1–3 ms	Significant cosmetic impr.
Holme et al. (23)	2005	1	72/F	Nose	72	Intralesional steroid therapy.	Not satisfactory
Verma et al. (24)	2005	1	52/F	Shoulder, face	Nk	Oral dapsone therapy 100 mg daily × 3 months Local infiltration of triamcinolone acetonide 20 mg/ml combined with cryotherapy repeated at weekly intervals for 6 weeks Excision followed by grafting Fresh nodule 10 weeks after surgery: intralesional infiltration of triamcinolone acetonide	No response Partial flattening of the lesions Completely removed Satisfactory results
Barnadas et al. (5)	2006	1	49/M	Cheeks	108	Topical tacrolimus 0.1%	Mild impr.
Eetam et al. (25)	2006	1	41/F	Nose, cheek	84	Topical pimecrolimus cream 1% twice a day × 2 months.	CR
Marcovel et al. (26)	2006	1	64/M	Forehead, preauricular region	96	Topical corticosteroids Topical tacrolimus 0.1% ointment	No response Significant impr.

Supplementary material to article by C. Lindhaus and P. Elsner "Granuloma Faciale Treatment: A Systematic Review"

Mashood (27)	2006	1	nk/F	Face		Combination of cryotherapy and intralesional corticosteroids	Excellent results
Panagiotopoulos et al. (28)	2006	1	58/M	Cheeks	Nk	2 × Cryotherapy: open-spray technique, 2 × 20 s	Successful
Panagiotopoulos et al. (28)	2006	1	44/F	Nose	Nk	2 × Cryotherapy: open-spray technique, 2 × 30 s	Successful
Panagiotopoulos et al. (28)	2006	1	56/M	Cheek	Nk	Cryotherapy: open-spray technique, 1 × 20 s	Successful
Panagiotopoulos et al. (28)	2006	1	55/F	Cheek	Nk	2 × Cryotherapy: open-spray technique, 2 × 30 s	Successful
Panagiotopoulos et al. (28)	2006	1	52/F	Front	Nk	Contact cryo-probe technique, 2 × 20s	Successful
Panagiotopoulos et al. (28)	2006	1	55/M	Forehead, cheeks	Nk	3 × Contact cryo-probe technique, 2 × 15s	Successful
Panagiotopoulos et al. (28)	2006	1	48/M	Forehead, cheek	Nk	3 × Contact cryo-probe technique, 2 × 10 s	Successful
Panagiotopoulos et al. (28)	2006	1	46/M	Nose, cheeks	Nk	3 × Cryotherapy: open-spray technique, 2 × 20 s	Successful
Panagiotopoulos et al. (28)	2006	1	36/M	Cheeks	Nk	2 × Cryotherapy: open-spray technique, 2 × 15 s	Successful
Requena et al. (29)	2006	1	52/M	Nose, forehead, cheeks	240	Dapsone 100 mg/day Excision of nasal lesions.	No response Good response
De et al. (30)	2007	1	38/M	Neck	168	Intralesional corticosteroids and dapsone (100 mg/day).	No impr. after 1 month
Khaled et al. (31)	2007	1	49/M	Nose	6	1 session of pulsed-dye laser	Subsequent impr.
Jedlicková et al. (32)	2008	1	60/M	Cheeks	Nk	Intermittent topical corticosteroids Cryospray treatment with liquid nitrogen Tacrolimus 0.1% ointment twice a day	Not satisfactory Without significant effect Complete remission
Chung et al.	2009	1	40/M	Glabella	18	Oral dapsone therapy	No benefit
Patterson & Coutts (33)	2009	1	46/M	Forehead, preauricular area	7	Topical 0.1% tacrolimus ointment twice daily	CR
Perez-Robayna et al. (34)	2009	1	90/M	Nose	6	Topical corticosteroids Topical 0.1% tacrolimus ointment twice daily.	No response Successful
Thiyaratnam et al. (35)	2009	1	58/M	Cheek	3	0.5 ml intralesional triamcinolone 4 mg/ml and tacrolimus ointment 0.1% twice daily.	Moderate impr.
Tomson et al. (36)	2009	1	50/M	Nose	96	2 × liquid nitrogen cryotherapy Tacrolimus 0.1% ointment twice daily	Minimal effect Good response
Tomson et al. (36)	2009	1	65/M	Cheeks	8	Mometasone furoate 0.1% cream, Topical tacrolimus 0.03% ointment twice daily	Transient impr. CR
Cecchi et al. (37)	2010	1	58/M	Nose	10	Mid- to high-potency topical corticosteroids Tacrolimus 0.1% ointment twice daily	Transient impr. Successful
Abdullah & Abbas (38)	2011	1	37/F	Cheek	Nk	Potent topical steroid	Successful
Caldarola et al. (39)	2011	1	72/M	Forehead, cheek	3	0.1 % tacrolimus ointment twice daily	Successful
Fikrle & Pizinger (40)	2011	1	57/M	Forehead	Nk	Local steroid therapy Cryotherapy	No benefit No benefit
Fikrle & Pizinger (40)	2011	1	76/M	Forehead, cheek	Nk	PDL system (Vbeam, Candela, Boston, MA, USA, 595 nm) 7-mm overlapping spot at 9–10 J/cm ² and a pulse duration of 1.5 ms, 3 sessions needed	Excellent No benefit No benefit
Fikrle & Pizinger (40)	2011	1	57/F	Cheek	Nk	Local steroid therapy Cryotherapy PDL system (Vbeam, Candela, 595 nm) 7-mm overlapping spot at 9–10 J/cm ² and a pulse duration of 1.5 ms, 3 sessions needed	Very good No benefit No benefit
Fikrle & Pizinger (40)	2011	1	55/F	Cheek	Nk	Local steroid therapy Cryotherapy PDL system (Vbeam, Candela, 595 nm) 7-mm overlapping spot at 9–10 J/cm ² and a pulse duration of 1.5 ms, 5 sessions needed	Excellent No benefit No benefit
Herscovitch et al. (41)	2011	1	63/F	Cheek	120	Intralesional triamcinolone (5 mg/ml) injections 2 vascular-beam laser (pulsed-dye) treatments	Excellent Moderate impr. Minimal impr.
Hruza & Amarati (42) 1999/2011	2011	1	41/M	Nose	24	585-nm pulsed dye laser.	Successful
Leite et al. (43)	2011	1	78/M	Scalp	3	Intralesional corticosteroids (3 sessions) Pulsed dye laser (PDL – 5 treatments, 585 nm wavelength emission and a pulse duration of 20 ms	Some impr. Marked impr.
Nogueira et al. (44)	2011	1	68/M	Nose	3	Monthly intralesional injections of methyl-prednisolone and oral dapsone (100 mg daily × 4 months)	Residual hyperpigmentation
Gupta (45)	2012	1	35/F	Cheek, forehead, shoulder, upper arms	60	Intralesional triamcinolone acetonide 10 mg/ml injection monthly + oral dapsone therapy 100 mg twice daily for approximately 1 year Six sessions of cryotherapy once monthly Topical tacrolimus 0.1% ointment twice daily	No benefit No benefit Relevant impr.
De Oliveira et al. (6)	2012	1	54/M	Face	Nk	Topical steroid + oral dapsone therapy + electrocoagulation	Relapse after 4 years
De Oliveira et al. (6)	2012	1	36/F	Face	Nk	Topical steroid + electrocoagulation	Relapse after 3 years
De Oliveira et al. (6)	2012	1	55/F	Face	Nk	Topical steroid + oral dapsone therapy + electrocoagulation	Relapse after 2 years
De Oliveira et al. (6)	2012	1	41/F	Face	Nk	Topical steroid + electrocoagulation	Clinical success

Supplementary material to article by C. Lindhaus and P. Elsner "Granuloma Faciale Treatment: A Systematic Review"

Singh et al. (46)	2013	1	33/M	Face	168	Intralesional triamcinolone acetonide 40 mg/ml every 4 weeks × 6 months Intralesional triamcinolone 40 mg/ml every 4 weeks with topical tacrolimus.	No response Slight flattening
Teixeira et al. (47)	2013	1	40/M	Shoulder, face	48	Intralesional corticosteroid and prednisone Oral dapsone therapy 100 mg daily	No response Partial impr.
Surana et al. (48)	2013	1	60/M	Distal extremities	8	Oral dapsone therapy 100 mg/day × 2 months potent corticosteroid	No sign. response Significant impr.
Babalola et al. (49)	2014	1	62/M	Nose	Nk	3 × intralesional triamcinolone (5 mg/ml) at 2-month interval 2 months topical mometasone 0.1% 6-month doxycycline (twice daily dose at 20 mg). Topical dapsone 5% gel (Aczone®) twice daily	Not successful Not successful Not successful Near-complete resolution Not successful
Bakkour & Madan (50)	2014	1	50/M	Nose	24	Clobetasol propionate 0.05% cream twice daily × 8 week Intralesional triamcinolone 10 mg/ml and oral dapsone up to 150 mg daily Carbon dioxide laser (MCO 50plus; KLS Martin, Tuttlingen, Germany) in scanning mode (spot size 4–6 mm, power 22 W, 0.15-ms dwell time, 6–8 passes depending on thickness).	Not successful Restoration of the normal contour and no obvious scarring and minimal hypopigmentation
Dourmishev et al. (51)	2014	1	60/F	Nose, cheek	Nk	Chloroquine 250 mg orally twice daily and topical betamethasone valerate cream × 3 months. Topical 1% pimecrolimus cream twice daily × 3 months.	No benefit Highly satisfying cosmetic outcome
Nayak et al. (52)	2014	1	23/F	Temple, cheek	3	3 courses of injection of intralesional steroids at an interval of 3 weeks Topical tacrolimus ointment (0.1%) × 1 month Excision	No improvement Reduction in size No history of recurrence
Fumo et al. (53)	2015	1	63/M	Nose, cheeks	240	Dapsone, 100 mg a day for 6 months Tacrolimus ointment 0.1%, twice daily for 2 months Intralesional steroid injection of betamethasone 6 mg every 2 weeks for 2 months	No benefit No benefit Acceptable cosmetic improvement
Lima et al. (54)	2015	1	58/F	Face	120	2 intralesional corticosteroid infiltrations with a 30-day interval Topical tacrolimus 0.1%	Unsatisfactory Significant impr.
Sand & Thomsen (55)	2015	1	nk/M	Forehead	Nk	Adalimumab for 6 months	Without marked impr
Vassallo et al. (56)	2015	1	39/F	Forehead, cheeks	48	Topical tacrolimus Oral dapsone therapy	Partial regression CR
Vassallo et al. (56)	2015	1	30/M	Cheek	3	Topical tacrolimus	CR
Vassallo et al. (56)	2015	1	63/M	Nose	2	Systemic steroid and topical tacrolimus	CR
Vassallo et al. (56)	2015	1	38/F	Forehead	48	Topical tacrolimus	Partial regression
Vassallo et al. (56)	2015	1	67/M	Back	60	Topical tacrolimus	Partial regression
Vassallo et al. (56)	2015	1	32/F	Nose	12	Topical tacrolimus	Partial regression
Vassallo et al. (56)	2015	1	28/F	Cheeks	24	Oral dapsone therapy	Partial regression
Vassallo et al. (56)	2015	1	45/M	Nose: cutaneous, subcutaneous, mucosal involvement	18	Systemic steroid Oral dapsone therapy	Poor response CR
Vassallo et al. (56)	2015	1	73/M	Face	12	Topical tacrolimus	Complete
Vassallo et al. (56)	2015	1	56/F	Forehead, nose	180	Oral dapsone therapy Topical tacrolimus added	Partial regression CR
Paradisi et al. (57)	2016	1	72/M	Nose	24	Topical treatments with high-potency steroids and tacrolimus 0.1% ointment Laser vaporization with a double wavelength device (Youlaser MT apparatus, Quanta System, Solbiate Olona, Italy) emitting 10,600-nm and 1,540-nm wavelengths simultaneously. Spot-size 1 mm (pulse duration 0.25 ms, pulse delay 5 ms), power 8 and 10 W for the 1,540 and 10,600 nm wavelength, respectively.	Partial regression Restoration of the normal contour and no obvious scarring
Paradisi et al. (57)	2016	1	64/M	Nose, cheeks	72	Topical clobetasol propionate 0.05% ointment Laser vaporization with a double wavelength device (Youlaser MT apparatus, Quanta System, Solbiate Olona, Italy) emitting 10,600 nm and 1,540 nm wavelengths simultaneously. Spot size 1 mm (pulse duration 0.25 ms, pulse delay 5 ms), power 8 and 10 W for the 1,540 and 10,600 nm wavelength, respectively.	No response Restoration of the normal contour and no obvious scarring
Madan (58)	2011	1	51/M	Cheek	51	Topical corticosteroids Cryotherapy 5 PDL treatments at 2-month intervals (Candela ScleroPLUS, 8–10 J/cm ² , 585 nm, 7-mm spot, 1.5 ms, dynamic cooling device 30 ms spray, 30 ms delay). 16 PDL treatments at 2-month intervals (Candela V Beam Perfecta, 10–12 J/cm ² , 595 nm, 7-mm spot, 1.5 ms, dynamic cooling device 30 ms spray, 30 ms delay) 2 treatments with the CO ₂ laser at 3-month intervals (Sharplan 40°C CO ₂ laser, silk touch mode using a scanner device, 4-mm spot size, 12 W, 4 passes to the papillary dermis	No response No response Partial cosmetic impr., relapse after 2 years No response Excellent cosmetic improvement, no relapse after 3 years

Impr.: improvement; CR: complete resolution; Nk: not known; PDL: pulsed-dye laser